Paper42872124PubMed
Integrated Multi-Time-Point 18F-FAPI PET/CT and Immune Histopathology for Predicting Pathological Complete Response in Microsatellite-Stable Locally Advanced Rectal Cancer Treated With Neoadjuvant Radiotherapy, Chemotherapy, and Immunotherapy.
He M and 7 others. MedComm (2020), 2026.
Cite this record
ConductScience Library. Integrated Multi-Time-Point 18F-FAPI PET/CT and Immune Histopathology for Predicting Pathological Complete Response in Microsatellite-Stable Locally Advanced Rectal Cancer Treated With Neoadjuvant Radiotherapy, Chemotherapy, and Immunotherapy. Papers, record 42872124. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42872124
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Integrated Multi-Time-Point 18F-FAPI PET/CT and Immune Histopathology for Predicting Pathological Complete Response in Microsatellite-Stable Locally Advanced Rectal Cancer Treated With Neoadjuvant Radiotherapy, Chemotherapy, and Immunotherapy.
- Journal
- MedComm (2020)
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-15
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06608537 | A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer | Derived from the trial | Yes |
Source ClinicalTrials.gov
References44
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34651226 | Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. | Eur J Nucl Med Mol Imaging | 2022 | https://conductscience.org/library/papers/34651226 | PubMed |
| 2 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 3 | 38462629 | Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study. | Signal Transduct Target Ther | 2024 | https://conductscience.org/library/papers/38462629 | PubMed |
| 4 | 28939744 | Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. | Clin Cancer Res | 2017 | https://conductscience.org/library/papers/28939744 | PubMed |
| 5 | 35133200 | MRI Radiomics Model Predicts Pathologic Complete Response of Rectal Cancer Following Chemoradiotherapy. | Radiology | 2022 | https://conductscience.org/library/papers/35133200 | PubMed |
| 6 | 39668486 | Dual-Time Point 68 Ga-FAPI-04 PET/CT Improves Tumor Delineation and Cervical Lymph Node Metastasis Identification in Patients With Head and Neck Squamous Cell Carcinoma. | Clin Nucl Med | 2025 | https://conductscience.org/library/papers/39668486 | PubMed |
| 7 | 39353648 | Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer with [68Ga]Ga-FAPI-04 PET, [18F]FDG PET, and Contrast-Enhanced MRI: Lesion-to-Lesion Comparison with Pathology. | J Nucl Med | 2024 | https://conductscience.org/library/papers/39353648 | PubMed |
| 8 | 27550820 | The biology and function of fibroblasts in cancer. | Nat Rev Cancer | 2016 | https://conductscience.org/library/papers/27550820 | PubMed |
| 9 | 30877175 | 18F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer. | J Nucl Med | 2019 | https://conductscience.org/library/papers/30877175 | PubMed |
| 10 | 35063964 | Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35063964 | PubMed |
| 11 | 25483833 | The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. | Radiother Oncol | 2014 | https://conductscience.org/library/papers/25483833 | PubMed |
| 12 | 33054291 | Assessing tumor response to neoadjuvant chemoradiation in rectal cancer with rectoscopy and 18F-FDG PET/CT: results from a prospective series. | Rev Esp Enferm Dig | 2021 | https://conductscience.org/library/papers/33054291 | PubMed |
| 13 | 36813670 | FAPI-avid nonmalignant PET/CT findings: An expedited systematic review. | Semin Nucl Med | 2023 | https://conductscience.org/library/papers/36813670 | PubMed |
| 14 | 36917951 | B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity. | Cancer Cell | 2023 | https://conductscience.org/library/papers/36917951 | PubMed |
| 15 | 36387154 | Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer. | Front Oncol | 2022 | https://conductscience.org/library/papers/36387154 | PubMed |
| 16 | 8622014 | Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. | J Clin Oncol | 1996 | https://conductscience.org/library/papers/8622014 | PubMed |
| 17 | 34725214 | Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. | J Immunother Cancer | 2021 | https://conductscience.org/library/papers/34725214 | PubMed |
| 18 | 29626120 | A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. | J Nucl Med | 2018 | https://conductscience.org/library/papers/29626120 | PubMed |
| 19 | 30544541 | TGFβ Superfamily Members as Regulators of B Cell Development and Function-Implications for Autoimmunity. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/30544541 | PubMed |
| 20 | 33258746 | Comparison of 68Ga-FAPI and 18F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. | Radiology | 2021 | https://conductscience.org/library/papers/33258746 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| FLUDEOXYGLUCOSE F 18 | CHEMBL2030434 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2030434 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Cited by
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42872124
GET https://conductscience.org/api/papers/v1/42872124/references?page=2